Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BIO-TECHNE Corp (TECH) vs Yum China Holdings Inc (YUMC) Price & Performance

BIO-TECHNE CorpTrade
Yum China Holdings IncTrade

Price performance (Past 24H)

Key statistics

BIO-TECHNE Corp vs Yum China Holdings Inc — how do they compare? BIO-TECHNE Corp trades at $72.13 (market cap $11.24B), while Yum China Holdings Inc trades at $47.4 (market cap $16.49B). The key difference: Yum China Holdings Inc is the larger of the two by market cap, and Yum China Holdings Inc pays the higher dividend (2.41%). Which is the better fit depends on your goals.

TECHYUMC
Market Cap
$11.24B$16.49B
Sector
HealthConsumer Cyclical
52-Week High
$72.29$57.95
52-Week Low
$43.31$40.18
Enterprise Value
$11.32B$17.40B
Dividend Yield
0.44%2.41%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BIO-TECHNE Corp

Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.

Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.

Yum China Holdings Inc

YUMC trades at $47.72, down 0.98% on the day, with a bullish technical signal supported by moving averages and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $0.70, exceeding expectations, and completed the acquisition of Pizza Hut China in August 2026, enhancing brand control. Revenue growth remains robust at 13% year-over-year, with a net income margin of 7.84% and a P/E ratio of 17.48, indicating reasonable valuation.

Outlook is positive due to consistent earnings growth and strategic acquisitions, but risks include macroeconomic headwinds in China and competitive pressures. Analyst consensus is strongly bullish with a 26.21% upside potential, though investors should monitor consumer spending trends and integration of Pizza Hut operations for sustained performance.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BIO-TECHNE Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

Read more on TECH

About Yum China Holdings Inc

With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.

Read more on YUMC